SpeeDx and MolGen announce partnership for COVID-19 test solution Australian company SpeeDx and MolGen have announced an agreement

Australian company SpeeDx and MolGen have announced an agreement to collaborate on the supply and distribution of clinical diagnostics products and instrumentation across Europe and the Asia Pacific.

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, with distributors across Europe. SpeeDx specialises in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management

The new partnership with MolGen links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies’ technologies.

“This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”

In response to the increased demand for molecular testing workflow solutions over the past year in response to the pandemic, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2.

SpeeDx completes the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary PlexPCR technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.

“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology,” said Maarten de Groot, MolGen CEO. “During the COVID pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.

/Public Release. This material comes from the originating organization/author(s)and may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.